Bfsg LLC Grows Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Bfsg LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,863 shares of the biopharmaceutical company's stock after buying an additional 11,733 shares during the period. Bfsg LLC owned about 0.13% of Catalyst Pharmaceuticals worth $3,925,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in CPRX. Allspring Global Investments Holdings LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after buying an additional 50,888 shares in the last quarter. Rhumbline Advisers increased its position in Catalyst Pharmaceuticals by 0.3% during the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after buying an additional 952 shares in the last quarter. Principal Financial Group Inc. raised its stake in Catalyst Pharmaceuticals by 4.3% in the fourth quarter. Principal Financial Group Inc. now owns 600,488 shares of the biopharmaceutical company's stock valued at $12,532,000 after buying an additional 24,535 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 91.5% in the fourth quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock worth $1,241,000 after acquiring an additional 28,407 shares in the last quarter. Finally, Ieq Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter worth about $313,000. 79.22% of the stock is currently owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the transaction, the insider now owns 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock worth $5,879,369 over the last quarter. 10.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CPRX shares. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX traded down $0.33 during mid-day trading on Friday, hitting $22.48. The company's stock had a trading volume of 2,014,927 shares, compared to its average volume of 1,138,686. The business's fifty day moving average is $23.94 and its two-hundred day moving average is $22.89. The stock has a market cap of $2.74 billion, a price-to-earnings ratio of 14.32, a PEG ratio of 0.93 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.75 and a 1 year high of $26.58.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.